Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2012

View Archived Issues

Marketed anticancer drug shows potential to treat Alzheimer's disease

Trimel provides update on intranasal gel for female anorgasmia

NIH to fund development of next-generation biodefense vaccines

Small-molecule interferon receptor agonist holds promise to treat hepatitis C

Analyte-responsive microscale pumps designed at Penn State

Large-scale European phase III study to assess nilvadipine

Summit discloses phase I study plans for candidate DMD treatment

FDA approves second-generation prostate cancer test

Novel P13K inhibitors patented by Roche

Recruitment begins in phase II ISIS-APOCIIIRx trial

EpiTherapeutics divulges new GASC-1 inhibitors

Phase II ofatumumab/GSK-2110183 combination study enters recruitment phase

Novel metabotropic glutamate mGlu4 receptor modulators identified

Shire reports active fourth quarter 2011

RedHill Biopharma begins advanced-stage clinical trial of RHB-102

Bionor provides update on development of HIV vaccine

Glenveigh Medical digoxin antidote gets orphan drug designation

FDA accepts NDA for tafamidis

Edgemont Pharmaceuticals obtains license to market CPI-300 in U.S.

New serotonin receptor antagonists patented in Japan

Ono Pharmaceutical updates progress of third quarter of fiscal 2011

Bristol-Myers Squibb develops new candidate cancer therapeutics

Multicenter study validates prognostic tool for use in patients comatose after cardiac arrest

Renal function marker is associated with severity of cerebral small vessel disease

Pfizer presents novel candidate pain treatments

FDA approves new gel for male hypogonadism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...